Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
2024-516671-33-00Phase 3Suspended
- Sponsor
- AB Science
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Masitinib + riluzole with Placebo + riluzole (2 arms). Primary endpoint: Absolute change from baseline in ALSFRS-R score at week 48. Started Jan 2025; status: suspended.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-516671-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516671-33-00.